At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
AZD1236 +1 moredrug
Likely dose
AZD1236 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating AZD1236 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 74 participants across 14 sites in 5 countries.
Detailed Summary
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesBulgaria, Finland, Germany, Hungary, Slovakia
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Study CompletionMar 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartSep 1, 2008
Study CompletionMar 1, 2009
TodayJul 2, 2026
Posted 17.8 years ago
Interventions
AZD1236drug
oral tablet, 75 mg, twice daily during 6 weeks
Placebodrug
Dosing to match AZD1236